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Introduction {#s1}
============

Acute coronary syndrome (ACS) is diagnosed when patients present with unstable angina, non-ST-elevation myocardial infarction (MI), or ST-elevation MI. Such patients have a wide spectrum of risks for death and cardiovascular ischemic events.[@pone.0111167-Rouleau1]--[@pone.0111167-Daida1] Careful risk assessment of ACS patients helps clinicians determine prognosis and may therefore be useful in guiding management and providing valuable information to patients. [@pone.0111167-Boden1], [@pone.0111167-Nakatani1] To be clinically practical, a risk stratification model must be straightforward and use clinical risk factors that are readily ascertainable at hospital presentation.

Several scoring methods, including GRACE (Global Registry of Acute Coronary Events) [@pone.0111167-Fox1], TIMI (Thrombolysis in Myocardial Infarction) [@pone.0111167-Antman1], and PURSUIT (Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrillin Therapy) [@pone.0111167-Boersma1], are developed in order to distinguish ACS patients at the risk of adverse outcome, who may benefit most from aggressive therapies. However, there is no simple, convenience, and commonly accepted tool for assessing the risk of adverse clinical events such as MI, stroke, or death in patients with ACS. The CHADS~2~ (congestive heart failure; hypertension; age ≥75 years; type 2 diabetes; and previous stroke, transient ischemic accident \[TIA\], or thromboembolism \[doubled\]) score was originally used to estimate the risk of stroke in individuals with atrial fibrillation (AF) but is also a powerful predictor of stroke and death in patients with ischemic heart disease. [@pone.0111167-Henriksson1], [@pone.0111167-Crandall1] A high score may be an independent marker of poor prognosis in cardiovascular disease.

The CHA~2~DS~2~-VASc score (congestive heart failure; hypertension; age ≥75 years \[doubled\]; type 2 diabetes; previous stroke, TIA, or thromboembolism \[doubled\]; vascular disease; age 65--75 years; and sex category) extends the CHADS~2~ score by considering additional risk factors for stroke and was recently recommended in a guideline for antithrombotic therapy in patients with AF or atrial flutter.[@pone.0111167-Lip1]--[@pone.0111167-Fuster1] A previous study found that CHADS~2~ score could identify ACS patients at higher risk of adverse events and that the CHA~2~DS~2~-VASc and CHADS~2~ scores did not significantly differ in their power to predict mortality in ACS patients. [@pone.0111167-Poci1] However, as compared with CHADS~2~ score, each additional component of the CHA~2~DS~2~-VASc score, such as peripheral vascular disease, female sex, and age 65--74 years, was associated with worse clinical outcomes in ACS patients. As compared with CHADS~2~ score, the CHA~2~DS~2~-VASc score is believed to have better prognostic predictive value for clinical outcomes. However, no published studies have investigated the association of CHADS~2~ and CHA~2~DS~2~-VASc scores with adverse event in patients with ACS. We compared the performance of CHADS~2~ and CHA~2~DS~2~-VASc scores in predicting subsequent MI, stroke, and death in patients with ACS.

Methods {#s2}
=======

Study design {#s2a}
------------

In this prospective, nationwide, multicenter, non-interventional observational study, each participating site recruited 50--200 consecutive eligible patients. To ensure that the sample satisfactorily represented the ACS population, sites were selected by using data from the Scientific Committee of Taiwan Society of Cardiology. The accuracy of documentation was examined in 5% of case report forms at each recruiting site. Patient data collected included baseline characteristics such as risk factors for cardiovascular disease, clinical presentation, and in-hospital interventions, as well as medications prescribed and clinical outcomes. Participants were followed up at 3, 6, 9, and 12 months after discharge, and the data collected included medication use and clinical adverse events, including MI, stroke, and death.

Patient recruitment {#s2b}
-------------------

Patients were aged 20 years or older and were admitted to hospital within 24hours of presenting with symptoms of ACS. All patients who provided informed consent were eligible to be included in the study. Patients were excluded from this study if ACS was precipitated by comorbidity, such as trauma, if they were previously enrolled in this trial, or if they were participating in an investigational drug study.

This study was performed in accordance with the Declaration of Helsinki and good clinical practice. Ethics committee approval was obtained at all trial sites including China University Medical Hospital, Taoyuan General Hospital, Wan-Fang Hospital, Show Chwan Memorial Hospital, Chia-Yi Christian Hospital, Kuang Tien General Hospital, National Taiwan University Hospital, Cheng Ching Hospital, Sin Lau Hospital The Presbyterian Church of Taiwan, Tainan Municipal Hospital, Mackay Memorial Hospital, E-Da Hospital, Chi-Mei Hospital, Taichung Armed Forces General Hospital, Taipei Tzu Chi General Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital, Pingtung Christian Hospital, Lo-Tung Po-Ai Hospital, Far Eastern Memorial Hospital, National Cheng Kung University Hospital, National Taiwan University Hospital, Yun-lin Branch, Dalin Tzuchi General Hospital, Kee-lung Hospital, Taipei Veterans General Hospital, Cathay General Hospital, Kaohsiung Veterans General Hospital, Taipei Medical University Hospital, Shin Kong Wu Ho-Su Memorial Hospital, Changhua Christian Hospital, National Taiwan University Hospital, Chung Shan Medical University Hospita, Hualien Tzu Chi General Hospital, Mackay Memorial Hospital, Taitung Branch, Linkou Chang Gung Memorial Hospital, Hsin Chu General Hospital, Kaohsiung Chang Gung Memorial Hospital, Tri-Service General Hospital and Cheng-Hsin Hospital. Written informed consent was obtained from each patient.

Definition of ACS {#s2c}
-----------------

ACS was defined as a heterogeneous range of symptoms, from ST-elevation MI to unstable angina and non-ST-elevation MI, as previously described. [@pone.0111167-Shyu1] Briefly, ST-elevation MI was defined as presentation with acute chest pain, or overwhelming shortness of breath, together with persistent electrocardiographic ST elevation \>1 mm in 2 or more contiguous leads, or with a new or presumed new left-bundle branch block pattern, on electrocardiography. Presentation with acute chest pain, or overwhelming shortness of breath, with no ST elevation but with classical rise and fall of at least one cardiac enzyme (troponin or MB fraction of creatine kinase) was defined as non-ST-elevation MI. Presentation with acute chest pain, or overwhelming shortness of breath, with neither ST elevation nor abnormal cardiac enzymes was defined as unstable angina.

CHADS~2~, CHA~2~DS~2~-VASc and GRACE scores {#s2d}
-------------------------------------------

CHADS~2~ score was calculated for all patients by assigning 1 point each for the criteria age ≥75 years, hypertension, diabetes mellitus, and heart failure and 2 points for the criterion previous stroke or TIA. For the CHA~2~DS~2~-VASc, 2 points were assigned for history of stroke/TIA or thromboembolism and age ≥75 years and 1 point each was assigned for the criteria age 65--75 years, history of hypertension, diabetes mellitus, heart failure, female sex, and vascular disease (defined as prior MI, complex aortic plaque, carotid disease, and peripheral artery disease, including intermittent claudication, previous surgery or percutaneous intervention for the abdominal aorta or vessels of the lower extremities, and arterial and venous thrombosis). [@pone.0111167-Lip1], [@pone.0111167-Camm1] The cutoff values used for grouping CHADS~2~ and CHA~2~DS~2~-VASc scores were determined according to values used in earlier studies of the risk of stroke and atrial properties. [@pone.0111167-Camm1], [@pone.0111167-Park1], [@pone.0111167-Chao1] Besides, the GRACE risk score [@pone.0111167-Fox1] (age, Killip class, heart rate, systolic BP, ST-segment deviation and cardiac arrest at admission, elevated biomarkers of myocardial necrosis, and baseline creatinine level) were also calculated from data collected at admission.

Statistical analyses {#s2e}
--------------------

Sample size for the Taiwan ACS full-spectrum registry was calculated as follows. There are about 50,000 new ACS cases per year in Taiwan. On the basis of the known background incidence rate of 0.0025, a sample of 2,395 patients would achieve 80% power to detect an additional incidence rate of 0.003, with a precision of 0.2% and a 95% confidence interval (CI). Assuming a dropout rate of 20%, a sample of 3,000 was considered adequately representative.

Parameters were summarized using mean, median, standard deviation, and interquartile range, where appropriate, for continuous data, and counts or percentages for categorical data. For comparability between groups, the chi-squared test was used for categorical variables, and analysis of variance (ANOVA) was used for continuous variables. Univariate associations of variables with adverse events, including subsequent MI, stroke, and death, were assessed with multivariate logistic regression. For each variable, the hazard ratio (HR), 95% CI, and *P* value are provided. The cumulative adverse events curves were constructed according to the Kaplan-Meier method. All statistical tests were two-sided, and a p value of \<0.05 was considered to indicate statistical significance. Analyses were done using a time to first event approach, without double counting of events in analyses involving composite endpoints. Patients lost to follow-up were censored at the time of last contact, and their vital status was classified as alive and event-free at that time. We assessed the predictive accuracy of CHADS~2~ and CHA~2~DS~2~-VASC scores by using the receiver operating characteristic (ROC) curve analysis. The areas under the ROC (AUCs) for these 2 indices were compared by using De Long's method. Statistical analysis was performed using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA).

Results {#s3}
=======

Clinical characteristics of participants and predictors of acute coronary syndrome {#s3a}
----------------------------------------------------------------------------------

During the period from October 2008 through January 2010, 3,183 eligible patients were enrolled at 39 hospitals in Taiwan. The study population had a mean age of 64 years (range, 20--101 years) and comprised 2,483 (78%) men and 700 (22%) women. Of these 3,183 patients, 2,016 (63%) had hypertension, 1,138 (36%) had diabetes mellitus, 1,235 (39%) had hyperlipidemia, 172 (5%) had a history of congestive heart failure, and 287 (9%) had a history of stroke or TIA. In addition, 367 (12%) patients had vascular disease, including 315 with a history of MI and 71 with peripheral vascular disease.

[Table 1](#pone-0111167-t001){ref-type="table"} shows the baseline clinical characteristics of the patients, stratified using a cutoff value of 2 on the CHADS~2~ and CHA~2~DS~2~-VASC indices. The burden of previous cardiovascular disease was somewhat greater in patients with a CHADS~2~ or CHA~2~DS~2~-VASC score of ≥2. Hypertension was the most important risk factor among patients with a CHADS~2~ or CHA~2~DS~2~-VASC score of ≥2. CHADS~2~ and CHA~2~DS~2~-VASC scores were inversely associated with ST-elevation MI; however, non-ST-elevation MI and unstable angina were more frequent among those with a CHADS~2~ or CHA~2~DS~2~-VASC score of ≥2. CHADS~2~ and CHA~2~DS~2~-VASC scores were inversely associated with primary percutaneous coronary intervention and the level of the MB fraction of creatine kinase. Participants with higher CHADS~2~ and CHA~2~DS~2~-VASC scores were more likely to present with a high Killip class and greater LV systolic dysfunction. There was no significant difference in drug regimen at discharge (including use of dual antiplatelet therapy, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, and statins) between patients with a CHADS~2~ or CHA~2~DS~2~-VASC score of \<2 and those with higher scores.

10.1371/journal.pone.0111167.t001

###### Baseline characteristics of patients stratified using a cutoff value of 2 for CHADS~2~ and CHA~2~DS~2~-VASc scores.

![](pone.0111167.t001){#pone-0111167-t001-1}

  Variable                                            CHADS~2~ score   CHA~2~DS~2~-VASc score                                          
  -------------------------------------------------- ---------------- ------------------------ --------- -------------- -------------- ---------
  Age, years                                            58.3±12.1            71.5±12.1          \<0.001     53.4±9.4      70.9±11.6     \<0.001
  Age 65--75 years                                      439 (24.3)           313 (22.7)          0.16      122 (9.8)      630 (32.5)    \<0.001
  Age ≥75 years                                         129 (7.1)            679 (49.3)         \<0.001      0 (0)        808 (41.6)    \<0.001
  Male                                                 1,546 (85.7)          937 (68.0)         \<0.001   1,196 (96.3)   1,287 (66.3)   \<0.001
  Medical History                                                                                                                      
  Current smoker                                        946 (52.4)           367 (26.6)         \<0.001    774 (62.8)     539 (27.6)    \<0.001
  Hypertension                                          734 (41.2)          1,282 (93.5)        \<0.001    421 (33.9)    1,595 (82.2)   \<0.001
  Diabetes                                              208 (11.6)           930 (67.7)         \<0.001    122 (9.8)     1016 (52.3)    \<0.001
  Hyperlipidemia                                        599 (33.6)           636 (46.4)         \<0.001    402 (32.8)     833 (42.9)    \<0.001
  Congestive heart failure                               12 (0.7)            160 (11.6)         \<0.001     3 (0.2)       169 (8.7)     \<0.001
  Previous CAD                                          275 (15.2)           507 (36.8)         \<0.001    115 (9.3)      667 (34.3)    \<0.001
  Previous myocardial infarction                        107 (21.3)           208 (31.9)         \<0.001     25 (2.0)      290 (14.9)    \<0.001
  Previous stroke/TIA                                     0 (0)              287 (20.8)         \<0.001      0 (0)        287 (14.8)    \<0.001
  Peripheral arterial disease                            13 (0.7)             58 (4.2)          \<0.001     2 (0.2)        69 (3.6)     \<0.001
  Vascular disease[§](#nt103){ref-type="table-fn"}      119 (6.6)            259 (18.8)         \<0.001     27 (2.2)      340 (17.5)    \<0.001
  History of atrial fibrillation                         30 (1.7)             73 (5.3)          \<0.001     8 (0.6)        95 (4.9)     \<0.001
  Chronic kidney disease                                314 (17.4)           609 (44.2)         \<0.001    171 (13.8)     752 (38.7)    \<0.001
  COPD                                                   40 (2.2)             83 (6.0)          \<0.001     14 (1.1)      109 (5.6)     \<0.001
  Clinical presentation                                                                                                                
  ST-elevation MI                                      1,120 (62.0)          583 (42.3)         \<0.001    822 (66.2)     881 (45.4)    \<0.001
  Non-ST elevation MI                                   361 (20.0)           489 (35.5)         \<0.001    222 (17.9)     628 (32.4)    \<0.001
  Unstable angina                                       324 (18.0)           306 (22.2)         \<0.001    198 (15.9)     432 (22.3)    \<0.001
  Killip class ≥III at admission                        238 (13.2)           289 (21.0)         \<0.001    135 (10.9)     392 (20.2)    \<0.001
  CK-MB maximum, median ug/L                            76.8±131.3           46.6±81.3          \<0.001    83.2±138.2     51.5±92.5     \<0.001
  LVSD (LVEF\<40%)                                      171 (9.5)            220 (16.0)         \<0.001    102 (8.2)      289 (14.9)    \<0.001
  Procedures                                                                                                                           
  Fibrinolysis therapy                                   33 (2.5)             22 (2.6)           0.89       22 (2.3)       33 (2.7)      0.68
  PCI                                                  1,588 (88.1)         1,092 (79.5)        \<0.001   1,111 (89.6)   1,569 (81.0)   \<0.001
  Primary PCI                                          1,016 (56.3)          490 (35.6)         \<0.001    725 (58.4)     781 (40.2)    \<0.001
  Rescue PCI                                             29 (2.1)             12 (1.4)           0.26       21 (2.2)       20 (1.6)      0.34
  CABG                                                   49 (2.7)             57 (4.1)           0.03       26 (2.1)       80 (4.1)      0.002
  Medication at discharge                                                                                                              
  Dual antiplatelet therapy                            1,351 (74.8)         1,034 (75.0)         0.93      923 (74.3)    1,462 (75.3)    0.53
  ACEi/ARB                                             1,157 (64.1)          848 (61.5)          0.07      769 (61.9)    1,236 (63.9)    0.32
  β-blockers                                            988 (54.7)           712 (51.7)          0.05      653 (52.6)    1,047 (53.9)    0.45
  Statin therapy                                       1,091 (60.4)          833 (60.4)          1.00      745 (60.0)    1,179 (60.7)    0.67
  VKA                                                    34 (1.9)             33 (2.4)           0.89       26 (2.1)       41 (2.1)      0.69

Values are presented as number (%) or mean ± SD.

ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CK-MB, MB fraction of creatine kinase; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; LVSD, left ventricle systolic dysfunction; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; VKA, vitamin K antagonist.

Vascular disease defined as previous myocardial infarction or peripheral arterial obstructive disease.

CHADS~2~ and CHA~2~DS~2~-VASc scores and prediction of subsequent MI, stroke, and death {#s3b}
---------------------------------------------------------------------------------------

Rates of MI, stroke, and death increased with increasing CHADS~2~ and CHA~2~DS~2~-VASc scores ([Fig. 1](#pone-0111167-g001){ref-type="fig"}). [Figure 2](#pone-0111167-g002){ref-type="fig"} shows the HRs for adverse events in relation to CHADS~2~ and CHA~2~DS~2~-VASc scores in patients with ACS. The risk of adverse events progressively increased as CHADS~2~ and CHA~2~DS~2~-VASc scores increased. Clinical outcomes during follow-up, in relation to CHADS~2~ and CHA~2~DS~2~-VASC scores at the cutoff value of 2, are summarized in [Table 2](#pone-0111167-t002){ref-type="table"}. Patients with CHADS~2~ or CHA~2~DS~2~-VASC scores of \>2 had higher risks of stroke and death. Overall, a CHADS~2~ or CHA~2~DS~2~-VASC score of \>2 was associated with higher risks of MI, stroke, and death during follow-up.

![Rates of adverse events, including myocardial infarction (MI), stroke, or death, according to CHADS~2~ and CHA~2~DS~2~-VASc scores.\
The rate of MI, stroke, or death increased as CHADS~2~ (A) and CHA~2~DS~2~-VASc (B) scores increased.](pone.0111167.g001){#pone-0111167-g001}

![Adjusted hazard ratios for the composite endpoint myocardial infarction (MI), stroke, or death, in relation to CHADS~2~ or CHA~2~DS~2~-VASc scores, in patients with acute coronary syndrome.\
The risk of MI, stroke, or death progressively increased with each unit increase in CHADS~2~ and CHA~2~DS~2~-VASc scores. The reference groups are patients with scores of 0. \* And § are defined as p\<0.001 vs. CHADS~2~ and CHA~2~DS~2~-VASc scores of 0, respectively.](pone.0111167.g002){#pone-0111167-g002}

10.1371/journal.pone.0111167.t002

###### Clinical outcomes during follow-up stratified using a cutoff value of 2 for CHADS~2~ and CHA~2~DS~2~-VASc scores.

![](pone.0111167.t002){#pone-0111167-t002-2}

  Variable                                   CHADS~2~ score   CHA~2~DS~2~-VASc score                                    
  ----------------------------------------- ---------------- ------------------------ --------- ---------- ------------ ---------
  Myocardial infarction or stroke               61 (3.4)             89 (6.5)          \<0.001   40 (3.2)   110 (5.7)     0.001
  Myocardial infarction                         49 (2.7)             52 (3.8)           0.09     32 (2.6)    69 (3.6)     0.13
  Stroke                                        12 (0.7)             39 (2.8)          \<0.001   8 (0.6)     43 (2.2)    \<0.001
  Death                                         52 (2.9)            159 (11.5)         \<0.001   12 (1.0)   199 (10.3)   \<0.001
  Myocardial infarction, stroke, or death      111 (6.2)            227 (16.5)         \<0.001   51 (4.1)   287 (14.8)   \<0.001

Values are presented as number (%) or mean ± SD.

At a cutoff value of 2, a higher CHADS~2~ or CHA~2~DS~2~-VASC score was significantly associated with rates of MI, stroke or death, before and after adjustment for potential confounders ([Table 3](#pone-0111167-t003){ref-type="table"}). The risk of subsequent MI, stroke, or death increased with every unit increase in CHADS~2~ or CHA~2~DS~2~-VASC score. After adjustment, the HR for future MI, stroke, or death per unit increase in CHADS~2~ and CHA~2~DS~2~-VASC scores was 1.44 (95% CI 1.30--1.58, p\<0.001) and 1.36 (95% CI 1.26--1.46, p\<0.001), respectively.

10.1371/journal.pone.0111167.t003

###### Hazard ratios for myocardial infarction, stroke, or death according to baseline CHADS~2~ and CHA~2~DS~2~-VASc scores.

![](pone.0111167.t003){#pone-0111167-t003-3}

  Characteristic                                            Unadjusted, HR (95% CI)   P Value   Adjusted, HR (95% CI)[§](#nt106){ref-type="table-fn"}   P Value
  -------------------------------------------------------- ------------------------- --------- ------------------------------------------------------- ---------
  Myocardial infarction or stroke                                                                                                                      
  CHADS~2~≥2 vs \<2                                            2.03 (1.46--2.81)      \<0.001                     1.87 (1.28--2.72)                      0.001
  CHADS~2~ score[†](#nt107){ref-type="table-fn"}               1.28 (1.13--1.44)      \<0.001                     1.25 (1.08--1.44)                      0.002
  CHA~2~DS~2~-VASc ≥2 vs \<2                                   1.72 (1.19--2.48)       0.004                      1.63 (1.10--2.47)                      0.02
  CHA~2~DS~2~-VASc score[†](#nt107){ref-type="table-fn"}       1.18 (1.08--1.29)      \<0.001                     1.18 (1.06--1.31)                      0.002
  Death                                                                                                                                                
  CHADS~2~≥2 vs \<2                                            4.40 (3.12--6.06)      \<0.001                     3.17 (2.24--4.47)                     \<0.001
  CHADS~2~ score[†](#nt107){ref-type="table-fn"}               1.74 (1.58--1.92)      \<0.001                     1.60 (1.41--1.80)                     \<0.001
  CHA~2~DS~2~-VASc ≥2 vs \<2                                   11.5 (6.42--20.8)      \<0.001                     8.52 (4.48--16.2)                     \<0.001
  CHA~2~DS~2~-VASc score[†](#nt107){ref-type="table-fn"}       1.62 (1.50--1.75)      \<0.001                     1.55 (1.42--1.70)                     \<0.001
  Myocardial infarction, stroke or death                                                                                                               
  CHADS~2~≥2 vs \<2                                            2.74 (2.19--3.41)      \<0.001                     2.33 (1.81--2.99)                     \<0.001
  CHADS~2~ score[†](#nt107){ref-type="table-fn"}               1.52 (1.40--1.65)      \<0.001                     1.44 (1.30--1.58)                     \<0.001
  CHA~2~DS~2~-VASc ≥2 vs \<2                                   3.42 (2.58--4.53)      \<0.001                     2.98 (2.17--4.07)                     \<0.001
  CHA~2~DS~2~-VASc score[†](#nt107){ref-type="table-fn"}       1.41 (1.33--1.50)      \<0.001                     1.36 (1.26--1.46)                     \<0.001

HR = hazard ratio; other abbreviations as in [Tables 1](#pone-0111167-t001){ref-type="table"} and [2](#pone-0111167-t002){ref-type="table"}.

Adjusted for all clinical variables in [Table 1](#pone-0111167-t001){ref-type="table"} (except the 5 or 7 variables included in the CHADS~2~ and CHA~2~DS~2~--VASc scoring systems, respectively), LVEF, Killip class, chronic kidney disease and medication at discharge.

Per unit increase in the original 6- or 8-criteria CHADS~2~ and CHA~2~DS~2~-VASc scoring systems, respectively.

Kaplan-Meier survival analysis revealed that patients with a CHADS~2~ score of ≥2 had a higher rate of MI, stroke, or death than did those with lower CHADS~2~ scores (*P*\<0.001, log-rank test; [Fig. 3A](#pone-0111167-g003){ref-type="fig"}). Furthermore, a CHA~2~DS~2~-VASc score of ≥2 was also a significant predictor of an adverse event (*P*\<0.001, log-rank test; [Fig. 3B](#pone-0111167-g003){ref-type="fig"}). However, CHA~2~DS~2~-VASc score had better diagnostic performance in predicting the composite endpoint subsequent MI, stroke, or death, as compared with CHADS~2~ score. The AUC increased from 0.66 to 0.70, and the difference was statistically significant (p\<0.001), as shown in [Figure 4](#pone-0111167-g004){ref-type="fig"}. The GRACE risk score (AUC = 0.74) had better diagnostic accuracy in predicting adverse events compared with CHA~2~DS~2~-VASc score. (p\<0.001).

![Kaplan-Meier curves for the time to the composite endpoint of myocardial infarction (MI), stroke, or death, according to CHADS~2~ and CHA~2~DS~2~-VASc scores.\
Survival analysis showed that a CHADS~2~ score of ≥2 was associated with a higher event rate than a score of \<2 (*p*\<0.001; log-rank test) (A). In addition, a CHA~2~DS~2~-VASc score of ≥2 was a significant predictor of adverse events (*p*\<0.001; log-rank test) (B).](pone.0111167.g003){#pone-0111167-g003}

![Receiver operating characteristic (ROC) curves for CHADS~2~, CHA~2~DS~2~-VASc and GRACE scores predicting myocardial infarction (MI), stroke, or death.\
Diagnostic performance in predicting MI, stroke, or death was better for CHA~2~DS~2~-VASc score than for CHADS~2~ score. The area under the ROC curve (AUC) increased from 0.66 to 0.70, and the difference was statistically significant (*p*\<0.001). Besides, the diagnostic accuracy in predicting adverse events was better for GRACE score than for CHA~2~DS~2~-VASc score (AUC 0.74 vs. 0.70, *p*\<0.001).](pone.0111167.g004){#pone-0111167-g004}

CHA~2~DS~2~-VASc score and subsequent adverse events in patients with a CHADS~2~ score of 0 or 1 {#s3c}
------------------------------------------------------------------------------------------------

A subgroup analysis of the 1805 patients with CHADS~2~ scores of 0 or 1 revealed that 111 (6%) had a subsequent MI, stroke, or death, and the rate progressively increased from 3.0% (in patients with CHA~2~DS~2~-VASc scores of 0) to 33.3% (in patients with CHA~2~DS~2~-VASc scores of 4) (p\<0.001; [Fig. 5A](#pone-0111167-g005){ref-type="fig"}). Using a CHA~2~DS~2~-VASc score of 2 as the cutoff point, patients with a score of ≥2 had a higher event rate than did those with a CHA~2~DS~2~-VASc score of \<2 (10.7% vs. 4.1%, p\<0.001; [Fig. 5B](#pone-0111167-g005){ref-type="fig"}).

![Flowchart of adverse event rates and risk scores in the patients with CHADS~2~ score of 0 or 1.\
(A) Rate of MI, stroke, or death in patients with a CHADS~2~ score of 0 or 1, according to CHA~2~DS~2~-VASc score. The rate of myocardial infarction (MI), stroke, or death progressively increased, from 3.0% to 33.3%, with increasing CHA~2~DS~2~-VASc score. (B) The flowchart shows the rate of MI, stroke, or death in patients stratified by CHADS~2~ and CHA~2~DS~2~-VASc scores.](pone.0111167.g005){#pone-0111167-g005}

Discussion {#s4}
==========

Principal findings {#s4a}
------------------

In this study of a cohort of patients with ACS, CHADS~2~ and CHA~2~DS~2~-VASc scores were helpful and convenient indices for predicting subsequent MI, stroke, or death. CHAD~2~DS~2~-VASc score was useful for further risk stratification for clinical outcome among patients with CHADS~2~ scores of 0 or 1. The usefulness of this simple and popular scoring system allows clinicians to summarize the overall risk of MI, stroke, and death in patients with ACS.

CHADS~2~ score in patients with ACS {#s4b}
-----------------------------------

The CHADS~2~ score is a risk index for predicting stroke in patients with AF and can be used to guide anticoagulation therapy. [@pone.0111167-Fuster2], [@pone.0111167-JohnCamm1] A previous study found that CHADS~2~ score predicted clinical outcomes in ACS patients with and without AF. [@pone.0111167-Poci1] It is reasonable to assume that CHADS~2~ score is valuable in ACS, since each of its components is a prognostic risk factor for ischemic heart disease [@pone.0111167-Gustafsson1], [@pone.0111167-Avezum1] and stroke. [@pone.0111167-Das1], [@pone.0111167-Sarwar1] Furthermore, a previous study reported that heart failure, hypertension history, increasing age, and diabetes were independent risk factors for long-term mortality in patients with acute MI. [@pone.0111167-Gustafsson1] This agrees with our finding that 7% of the present ACS patients with a CHADS~2~ score of \<2, vs. 17% with a score of ≥2, had subsequent MI, stroke, or death. Using multivariate models, we found that CHADS~2~ score was a powerful predictor of subsequent adverse events after ACS. These findings extend the usefulness of the CHADS~2~ score in predicting clinical outcomes in patients with ACS. The CHADS~2~ score may help identify treatable underlying conditions in patients with ACS, thereby decreasing subsequent risk.

CHA~2~DS~2~-VASc scores in patients with ACS {#s4c}
--------------------------------------------

The new CHA~2~DS~2~-VASc score extends the CHADS~2~ score by adding the criteria age 65--74 years, vascular disease, and female sex, which increases the predictive value of the CHADS~2~ for thromboembolic events with low event rates in low-risk patients. [@pone.0111167-Lip1], [@pone.0111167-Camm1] A previous study found that CHADS~2~ and CHA~2~D~2~-VASc scores did not significantly differ in relation to prediction of mortality in ACS patients; however, it is important to note that these scoring systems were developed to predict stroke and thromboembolism, not mortality. [@pone.0111167-Poci1] We found that, as compared with CHADS~2~ score, CHA~2~DS~2~-VASc score had better diagnostic performance in predicting subsequent adverse events. In addition, the AUC significantly increased, from 0.66 to 0.70. Moreover, CHA~2~DS~2~-VASc score could further predict risk of subsequent MI, stroke, or death in ACS patients with CHADS~2~ scores of 0 and 1.

The impact of female sex on ACS has been investigated: as compared with men, women had more complications during hospitalization and a higher mortality rate.[@pone.0111167-Herman1]--[@pone.0111167-Hochman2] Women and men with ACS had a different clinical outcome, which reflects pathophysiologic and anatomic differences between sexes. [@pone.0111167-Hochman2] Peripheral vascular disease is often complicated by ischemic episodes, not only in peripheral circulation but also in coronary and cerebral vessels. [@pone.0111167-Dormandy1], [@pone.0111167-Leng1] The rate of cardiovascular mortality among patients with peripheral vascular disease was three-fold that of age-matched controls. [@pone.0111167-Leng2], [@pone.0111167-Dormandy2] Furthermore, the presence of peripheral vascular disease in conjunction with ACS is associated with substantial mortality and morbidity. [@pone.0111167-AlThani1] Given that age does not have a binary effect on the risk of adverse events and that age ≥75 years was associated with high risk, it is understandable that the criterion age 65--74 years, in combination with another risk factor, was associated with increased risk in ACS patients.^23^ It was estimated that 60% of ACS cases were people aged ≥65 years and that 30% were people aged ≥75 years. In addition, as many as 80% of deaths related to ACS occur in patients aged ≥65 years. [@pone.0111167-Goldberg1], [@pone.0111167-Roger1] Taken together, these findings suggest that the risk of subsequent MI, stroke, or death increases with the combination of these additional risk factors in the CHA~2~DS~2~-VASc score.

The more complicated GRACE score provided a better prediction for subsequent adverse events than the simpler CHA~2~DS~2~-VASc score according to the ROC curve analysis. However, one great advantage of the CHA~2~DS~2~-VASc score is that it provides a comprehensive, convenience, and fast method for clinical physician in risk evaluation. No calculators or computers are needed for the risk stratification.

Clinical implications {#s4d}
---------------------

The CHADS~2~ scoring system was a simple tool for predicting adverse events among ACS patients. A CHADS~2~ score of ≥2 was associated with a 16.5% risk of adverse events in ACS patients. Moreover, the more detailed CHA~2~DS~2~-VASc scoring system could further discriminate the risk of developing adverse events among patients with a CHADS~2~ score of 0 or 1. The clinical utility of the CHA~2~DS~2~-VASc score should be emphasized, as it was generally believed that patients with a CHADS~2~ score of 0 or 1 were at low risk; however, among this subgroup, those with a CHA~2~DS~2~-VASc score of 4 have a rate of adverse events as high as 33.3%. These findings suggest that CHA~2~DS~2~-VASc score is useful in identifying ostensibly low-risk patients who are at risk of adverse events and optimizing management of such patients so as to lower such risk. However, this requires confirmation in a large-scale prospective trial.

Study limitations {#s4e}
-----------------

This study had several limitations. Patients at other sites might have risk profiles and subsequent outcomes that vary depending on differences in ACS treatment. In addition, adverse events among the present participants would have been missed if such episodes occurred at other hospitals. The incidences of adverse events in the present study may have been underestimated, which would have biased the results against a significant association of CHADS~2~ and CHA~2~DS~2~-VASc scores with adverse events in the present study.

Conclusion {#s5}
==========

CHADS~2~ and CHA~2~DS~2~-VASc scores can be used to estimate the risk of clinical adverse events in patients with ACS. Among patients with CHADS~2~ scores of 0 or 1, the CHA~2~DS~2~-VASc score was helpful in identifying patients who were at higher risk. These scoring systems could lead to optimization of therapy, which might reduce risks of subsequent adverse events.
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